Hasebe Hideyuki, Yokoya Tomoyo, Murakoshi Nobuyuki, Kurebayashi Nobutake
Division of Arrhythmology, Shizuoka Saiseikai General Hospital, Japan.
Cardiovascular Division, Faculty of Medicine, University of Tsukuba, Japan.
Intern Med. 2020 Jan 1;59(1):83-87. doi: 10.2169/internalmedicine.3430-19. Epub 2019 Sep 3.
Mutations in the cardiac sodium channel SCN5A can cause phenotypic overlap syndrome of long QT syndrome and Brugada syndrome. However, Brugada-type ST elevations in patients with overlap syndrome are often concealed, which creates a diagnostic challenge. A 38-year-old man was admitted due to ventricular fibrillation (VF). The 12-lead electrocardiogram showed a prolonged QT interval and saddleback-type ST elevation. Pilsicainide administration induced coved-type ST elevation and VF triggered by a single premature ventricular contraction. A genetic analysis showed an SCN5A c.5350G>A p.E1784K mutation. The present case suggests the importance of a drug administration test being performed in the clinical management of overlap syndrome.
心脏钠通道SCN5A的突变可导致长QT综合征和Brugada综合征的表型重叠综合征。然而,重叠综合征患者的Brugada型ST段抬高常被隐匿,这给诊断带来了挑战。一名38岁男性因室颤(VF)入院。12导联心电图显示QT间期延长和鞍背型ST段抬高。给予吡西卡尼后诱发了穹窿型ST段抬高和由单个室性早搏触发的室颤。基因分析显示存在SCN5A c.5350G>A p.E1784K突变。本病例提示在重叠综合征的临床管理中进行药物激发试验的重要性。